Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 9;17(12):e1010078.
doi: 10.1371/journal.ppat.1010078. eCollection 2021 Dec.

Current state of Ebola virus vaccines: A snapshot

Courtney Woolsey  1   2 , Thomas W Geisbert  1   2
Affiliations

Current state of Ebola virus vaccines: A snapshot

Courtney Woolsey et al. PLoS Pathog. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: TWG is listed as a co-inventor on U.S. patent numbers 7,635,485; 8,017,130; 8,796,013 related to filovirus vaccines and has received no royalties from any filovirus vaccine. CW has declared that no competing interests exist.

Figures

Fig 1
Fig 1. Leading EBOV vaccines.
The most advanced vaccines in the US and Europe include Ervebo (rVSV-EBOV), Zabdeno/Mvabea (Ad26-ZEBOV/MVA-BN-Filo), and cAd3-EBOZ (with or without MVA-BN-Filo). These platforms use a viral vector to provoke an immune response, but, as illustrated, there are several distinctions among these 3 vaccines including vector virus, dose, efficacy, cell targets, and inclusion of a booster. Created with BioRender.com. Ad26, human adenovirus serotype 26; cAd3, chimpanzee adenovirus serotype 3; EBOV, Ebola virus (Zaire ebolavirus); EBOZ, Ebolavirus-Zaire species; EMA, European Medicines Agency; FDA, US Federal Drug Administration; GP, glycoprotein; i.u., infectious unit; MARV, Marburg virus; NIAID, National Immunology Allergy and Infectious Disease; NP, nucleoprotein; PHAC, Public Health Agency of Canada; rVSV, recombinant vesicular stomatitis virus; SUDV, Sudan virus; TAFV, Taï Forest virus; ZEBOV, Zaire ebolavirus.
See this image and copyright information in PMC

References

    1. Feldmann H, Sprecher A. Geisbert TW. Ebola. N Engl J Med. 2020;382(19):1832–42. doi: 10.1056/NEJMra1901594 . - DOI - PubMed
    1. Centers for Disease Control and Prevention. Ebola (Ebola virus disease): History of Ebola Virus Disease (EVD) Outbreaks [updated June 2021] [cited 2021 Oct 4]. Available from: http://www.cdc.gov/vhf/ebola/history/chronology.html.
    1. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al.. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–518. Epub 2016 Dec 23. doi: 10.1016/S0140-6736(16)32621-6 . - DOI - PMC - PubMed
    1. World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. 10 April 2019 meeting report. [cited 2021 Oct 4]. Available from: https://www.who.int/csr/resources/publications/ebola/ebola-ring-vaccinat....
    1. Masterson SG, Lobel L, Carroll MW, Wass MN, Michaelis M. Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. Front Immunol. 2018. May 9;9:1025. doi: 10.3389/fimmu.2018.01025 ; PubMed Central PMCID: PMC5954026. - DOI - PMC - PubMed

Publication types

MeSH terms